Analysis
Heidi Health raised $340 million in combined financing, according to PYMNTS and Tech Funding News: a $100 million equity Series C led by Blackbird, with Phoenix Court, Point72 Private Investments and Headline also participating, plus $240 million in non-dilutive growth financing from General Catalyst's Customer Value Fund. The equity round values the Australia-founded company at $900 million.
From NHS Scribe To Full Clinical Platform
Heidi was founded in Melbourne in 2019 by Dr. Thomas Kelly, Waleed Mussa and Yu Liu, launching originally as a clinical-training tool called Oscer before rebranding to Heidi Health in 2021. It started as an ambient AI medical scribe -- listening to doctor-patient conversations and generating clinical notes automatically -- and has since expanded into three adjacent products: Heidi Evidence, which surfaces point-of-care clinical guidelines during a consultation; Remote, a dedicated AI hardware device for clinical work; and Dictate, a standalone voice-to-text feature. That progression from a single notetaking wedge into a broader clinical-AI platform mirrors the path several enterprise AI companies have taken this year, expanding from one clearly-defined task into the adjacent workflow once the original product proved sticky.
“## From NHS Scribe To Full Clinical Platform Heidi was founded in Melbourne in 2019 by Dr.”
The scale is real: Heidi says it now supports roughly 2.8 million patient interactions every week, across 110 languages and 190 countries. That geographic and language breadth is a meaningful differentiator against most AI-scribe competitors -- including Nabla, Abridge and Suki in the US market -- which have concentrated primarily on English-language, US and UK healthcare systems. Heidi's origin serving Australia's and the UK's NHS-adjacent primary care markets appears to have pushed it toward multilingual support earlier than competitors focused on a single large English-speaking market.
The Non-Dilutive Structure Is The More Interesting Number
The $240 million from General Catalyst's Customer Value Fund is arguably the more telling number in this round than the $100 million equity raise. Customer Value Fund financing is structured around revenue performance rather than equity dilution, letting a company scale customer acquisition or infrastructure spend without giving up additional ownership at the same rate a pure equity round would require. For a healthcare AI company with recurring, provider-based revenue, this is a capital-efficient way to fund growth that a pure-software startup with less predictable revenue typically can't access on similar terms.
For founders in adjacent health-tech categories, Heidi's structure is worth studying directly: pairing a smaller, valuation-setting equity round with a much larger non-dilutive facility tied to revenue lets a company post a $340 million headline number while diluting founders and early investors at roughly a third of that scale. Expect more late-stage AI health-tech rounds to copy this exact structure as General Catalyst and similar funds scale their non-dilutive vehicles.
The risk sitting underneath the platform expansion is focus: ambient scribing, point-of-care guidelines, hardware and voice-to-text are four distinct product bets, and a company scaling all four simultaneously risks doing none of them as well as a more focused single-product competitor. What to watch next is whether Heidi's usage numbers show Evidence, Remote and Dictate genuinely gaining independent traction, or whether they remain secondary features bundled around the original scribe product that actually drives adoption.